Effectiveness of Complex Treatment of Patients with Chronic Heart Failure Taking into Account Immune System Condition

  • N. G. Virstiuk Ivano-Frankivsk National Medical University, Ivano-Frankivsk
  • O. E. Cherkashyna Ivano-Frankivsk National Medical University, Ivano-Frankivsk
Keywords: chronic heart failure, immune system, treatment


In order to evaluate glutargin and imunofan efficiency the changes of clinical manifestations and parameters of cellular and humoral immunity, oxidation-reduction processes, metabolic intoxication depending on CHF stage were studied in 96 patients suffering from arterial hypertension with chronic heart failure (CHF). Secondary immunodeficiency, activation of lipid peroxidation and metabolic intoxication increasing with CHF stage developed in patients with FC III CHF at stage II A and FC IV at stage II B according to NYHA. The use of glutargin and imunofan in complex treatment of the patients with CHF improves the effectiveness of treatment, the cellular and humoral immunity indices, reduces secondary immunodeficiency and metabolic intoxication.


Voronkov LH. “Path” of patients with chronic heart failure: as long and comfortable as possible. Sertseva nedostatnist. 2014; 1: 7-10.

Zharynova VYu. Modern possibilities of endothelial protecting therapy optimization in patients with CHF. Sertseva nedostatnist. 2013; 3: 45-53.

Riabenko DV. Pharmacotherapy of chronic heart failure in the XXI century: achievements and questions. Sertseva nedostatnist. 2014; 2: 24-33.

Michael Mahler, Pier-Luigi Meroni, Xavier Bossuyt, Marvin J. Fritzler Mahler Michael Current Concepts and Future Directions for the Assessment of Autoantibodies to Cellular Antigens Referred to as Anti-Nuclear Antibodies. Journal of Immunology Research. 2014; 18.

Pitt B, Latini R, Maggioni AP, Solomon SD, Smith BA, Wright M, Prescott MF, McMurray JV, Pitt B. Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study. European Journal of Heart Failure. 2011; 13: 755–764.

Sinagra E, Perricone G, Romano C, Cottone M. Heart failure and anti tumornecrosis factor-alpha in systemic chronic inflammatory diseases. Eur. J. Intern. Med. 2013 Jan 17.

Ueland T, Yndestad A, Dahl CP et al. TNF revisited: osteoprotegerin and TNF-related molecules in heart failure. Curr. Heart Fail. Rep. 2012; 9 (2): 92-100.

Original Research